Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 4/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728688 | 0.88 | LSS (0.48) | MAPTHRH3LSSMCHR1KCNH2 | |
| SCHEMBL1728684 | 0.87 | HRH3 (0.39) | HRH3ACACBALDH1A1KMT2A | |
| SCHEMBL1729760 | 0.87 | LSS (0.47) | MAPTHRH3LSSMCHR1KCNH2 | |
| SCHEMBL1729124 | 0.87 | LSS (0.47) | MAPTHRH3LSSMCHR1KCNH2 | |
| SCHEMBL1728571 | 0.85 | LSS (0.41) | MAPTHRH3ACACBLSSMCHR1 | |
| SCHEMBL1729087 | 0.84 | MAPK14 (0.51) | HRH3LSSALDH1A1MCHR1 | |
| SCHEMBL6081167 | 0.84 | MCHR1 (0.42) | MAPTHRH3ACACBLSSMCHR1 | |
| SCHEMBL6080844 | 0.83 | MCHR1 (0.41) | MAPTHRH3ACACBLSSMCHR1 | |
| SCHEMBL6081620 | 0.83 | ALDH1A1 (0.50) | HRH3ACACBALDH1A1 | |
| SCHEMBL1728856 | 0.79 | HRH3 (0.42) | HRH3MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551810-B1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-11-30 | — | — | EP | disclosed |
| EP-1551810-B1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | SANOFI AVENTIS DEUTSCHLAND (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-7141561-B2 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | GPR119, GLP1R, SLC5A2 | MAPT 4703/4885POLB 4043/4885HRH3 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.